UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~October~~November 2917, 2025

PURE BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-14468

33-0530289

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

771 Jamacha Rd., #512

El Cajon, California

92019

(Address of principal executive offices)

(Zip Code)

9669 Hermosa Avenue Rancho Cucamonga, California		91730
(Address of principal executive offices)		(Zip Code)

(Former name or former address, if changed since last report)

Registrant’s telephone number, including area code: (619) 596-8600

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 25.02. ~~Results~~Departure of ~~Operations~~Directors ~~and~~or ~~Financial~~Certain ~~Condition~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On ~~October~~November 2919, 2025, PURE Bioscience, Inc. (the “Company”) ~~issued~~announced athat ~~press~~Jeffrey ~~release~~Kitchell ~~announcing~~has ~~financial~~been ~~results~~appointed ~~for~~as the ~~fiscal~~Company’s ~~year~~President, ~~ended~~in ~~July~~addition 31to his ongoing responsibilities as the Company’s Corporate Secretary, effective as of November 17, 2025 (the “Effective Date”). Robert Bartlett will continue as the Company’s Chief Executive Officer, principal executive officer and ~~related~~a ~~information.~~member Aof ~~copy~~the Company’s board of directors, but stepped down from the ~~press~~position ~~release~~of isPresident ~~attached~~effective as ~~Exhibit~~of 99the Effective Date.1.

~~The~~Mr. ~~information~~Kitchell, in55, ~~this~~has ~~Item~~served ~~2.02~~as isthe ~~being~~Company’s ~~furnished~~Vice ~~and~~President ~~shall~~of ~~not~~Operations besince ~~deemed~~April ~~“filed”~~2023. ~~for~~He ~~the~~also ~~purposes~~serves ofas ~~Section~~the 18Company’s Corporate ofSecretary, ~~the~~a ~~Securities Exchange~~role ~~Act~~he ofhas ~~1934~~had orsince ~~otherwise~~2019. ~~subject~~Mr. Kitchell oversees day-to-day operations, supports the ~~liabilities~~Company’s offunctions, and ~~that~~implements ~~Section~~new structures and processes. ~~The~~Mr. ~~information~~Kitchell inhas ~~this~~held ~~Item~~various 2roles since joining the Company in 2001.02 ~~shall~~In ~~not~~his bevarious ~~incorporated~~roles, byhe ~~reference~~managed ~~into~~the ~~any~~Company’s ~~registration~~legal ~~statement~~affairs orand ~~other~~helped ~~document~~secure ~~filed~~its ~~with~~intellectual property. Before joining the ~~Securities~~Company, ~~and~~Mr. ~~Exchange~~Kitchell ~~Commission~~held various leadership roles in companies ranging from small to large. Mr. Kitchell earned a Bachelor’s Degree in Business Administration from the University of Phoenix.

It is anticipated that Mr. Kitchell will enter into the Company’s standard form of indemnification agreement for the Company’s officers and participate in other compensation and benefit programs generally available to the Company’s executive officers. The terms of Mr. Kitchell’s employment with the Company otherwise remain unchanged.

Except as set forth above, there are no arrangements or understandings between Mr. Kitchell and any other persons pursuant to which he was named to this position with the Company. There are no family relationships between Mr. Kitchell and any of the Company’s directors or executive officers and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

The Company issued a press release announcing the appointment of Mr. Kitchell, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1	99Press Release, dated November 19, 2025.1	~~Press Release, dated October 29, 2025.~~
104	~~104~~Cover Page Interactive Data File (embedded within the Inline XBRL document).	~~Cover Page Interactive Data File (embedded within the Inline XBRL document)~~

* Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PURE BIOSCIENCE, INC.
Dated: October 29, 2025	By:	/s/ Robert F. Bartlett
Dated: November 19, 2025	By:	/s/ Robert F. Bartlett
		Robert F. Bartlett
		Chief Executive Officer

EXHIBIT INDEX

Exhibit Number		Description
99.1		Press Release, dated October 29, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

Filing Compare · PURE BIOSCIENCE, INC.